Patents Assigned to Autoimmune Technologies, LLC
  • Publication number: 20220280618
    Abstract: The present invention is directed to antibodies binding to and neutralizing Candida and methods for use thereof.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 8, 2022
    Applicants: The Administrators of the Tulane Educational Fund, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Autoimmune Technologies, LLC
    Inventors: Russell B. WILSON, Hong XIN, James E. ROBINSON
  • Publication number: 20210401984
    Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are trasfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IF?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
    Type: Application
    Filed: September 17, 2021
    Publication date: December 30, 2021
    Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Robert Francis GARRY, Luis Manuel BRANCO, Bruce Alan BUNNELL, Russell B. WILSON, Samuel E. HOPKINS
  • Patent number: 11123427
    Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are transfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 21, 2021
    Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
  • Patent number: 10537634
    Abstract: Immunogenic influenza hemagglutinin-derived peptide compositions described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide compositions comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein bound to an immunogenic carrier protein, such as an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide compositions described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: January 21, 2020
    Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Robert Francis Garry, Russell B. Wilson
  • Publication number: 20190282694
    Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are transfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
    Type: Application
    Filed: May 30, 2019
    Publication date: September 19, 2019
    Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
  • Publication number: 20190227078
    Abstract: An assay kit for use in detecting an anti-polyvinyl alcohol antibody (anti-PVAL), comprises: polyvinyl alcohol (PVAL) attached to a support material; and an indicator reagent comprising a binding member that is specific for a human antibody; wherein the binding member is conjugated to a detectable label, and the binding member is capable of forming a complex with an anti-PVAL antibody. The kit can be used in a method for detecting antipolyvinyl alcohol (anti-PVAL) antibodies in test samples, such as serum, which comprises combining a test sample (e.g., serum) with the PVAL-bound support material to form a binary complex of the PVAL with an anti-PVAL antibody in the sample, followed by reacting the indicator reagent with the binary complex to form a labeled ternary complex, and then detecting the presence or absence of the ternary complex.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 25, 2019
    Applicant: AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Russell B. WILSON, Kevin David SIMPSON
  • Patent number: 10357562
    Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: July 23, 2019
    Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC
    Inventors: Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
  • Patent number: 10330686
    Abstract: An assay method for detecting antipolyvinyl alcohol (anti-PVAL) antibodies in test samples, such as serum, is described. The method comprises combining a sample to be tested for an anti-PVAL antibody with polyvinyl alcohol (PVAL) to form a binary complex of the PVAL with an anti-PVAL antibody in the sample, followed by reacting an indicator reagent with the binary complex to form a labeled ternary complex, and then detecting the presence or absence of the ternary complex in the sample. Kits for performing the test are also described.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: June 25, 2019
    Assignee: Autoimmune Technologies, LLC
    Inventors: Russell B. Wilson, Kevin David Simpson
  • Publication number: 20190054168
    Abstract: Immunogenic influenza hemagglutinin-derived peptide compositions described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide compositions comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein bound to an immunogenic carrier protein, such as an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide compositions described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 21, 2019
    Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Robert Francis GARRY, Russell B. WILSON
  • Patent number: 10137194
    Abstract: Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such asbovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: November 27, 2018
    Assignees: The Admininstrators of the Tulane Educational Fund, Autoimmune Technologies, LLC
    Inventors: Robert Francis Garry, Russell B. Wilson
  • Publication number: 20180113124
    Abstract: An assay method for detecting antipolyvinyl alcohol (anti-PVAL) antibodies in test samples, such as serum, is described. The method comprises combining a sample to be tested for an anti-PVAL antibody with polyvinyl alcohol (PVAL) to form a binary complex of the PVAL with an anti-PVAL antibody in the sample, followed by reacting an indicator reagent with the binary complex to form a labeled ternary complex, and then detecting the presence or absence of the ternary complex in the sample. Kits for performing the test are also described.
    Type: Application
    Filed: October 20, 2016
    Publication date: April 26, 2018
    Applicant: AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Russell B. WILSON, Kevin David SIMPSON
  • Publication number: 20170258902
    Abstract: Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such asbovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
    Type: Application
    Filed: May 10, 2017
    Publication date: September 14, 2017
    Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Robert Francis GARRY, Russell B. WILSON
  • Patent number: 9725487
    Abstract: The present invention provides compositions and methods for treating a measles virus infection. A pharmaceutical composition comprises a polypeptide in a biocompatible pharmaceutical carrier, in which the polypeptide consists of at least a portion of SEQ ID NO: 5 or SEQ ID NO: 6. A method embodiment comprises administering the polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a measles infection.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: August 8, 2017
    Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC
    Inventors: Robert F. Garry, Russell B. Wilson
  • Patent number: 9649375
    Abstract: Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 16, 2017
    Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC.
    Inventors: Robert Francis Garry, Russell B. Wilson
  • Patent number: 9353157
    Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 31, 2016
    Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC
    Inventors: Robert F. Garry, Russell B. Wilson
  • Publication number: 20160129110
    Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
    Type: Application
    Filed: July 17, 2015
    Publication date: May 12, 2016
    Applicants: AUTOIMMUNE TECHNOLOGIES, LLC, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Robert Francis GARRY, Luis Manuel BRANCO, Bruce Alan BUNNELL, Russell B. WILSON, Samuel E. HOPKINS
  • Publication number: 20150239940
    Abstract: The present invention provides compositions and methods for treating a measles virus infection. A pharmaceutical composition comprises a polypeptide in a biocompatible pharmaceutical carrier, in which the polypeptide consists of at least a portion of SEQ ID NO: 5 or SEQ ID NO: 6. A method embodiment comprises administering the polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a measles infection.
    Type: Application
    Filed: May 13, 2015
    Publication date: August 27, 2015
    Applicant: AUTOIMMUNE TECHNOLOGIES, LLC
    Inventors: Robert F. GARRY, Russell B. WILSON
  • Patent number: 9101597
    Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 11, 2015
    Assignees: The Administration of the Tulane Educational Fund, Autoimmune Technologies, LLC
    Inventors: Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
  • Patent number: 9056900
    Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: June 16, 2015
    Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC.
    Inventors: Robert F. Garry, Russell B. Wilson
  • Publication number: 20140194347
    Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.
    Type: Application
    Filed: December 10, 2013
    Publication date: July 10, 2014
    Applicants: Autoimmune Technologies, LLC, The Administrators of the Tulane Educational Fund
    Inventors: Robert F. GARRY, Russell B. WILSON